

# APPLICATIONS


## LC-MS/MS Analysis Oxytocin (OT) and ARG-Vasopressin (AVP) in Human Plasma/Serum using Strata®-X-CW Solid Phase Extraction (SPE) and a Luna® PFP(2) HPLC Column

Xianrong (Jenny) Wei, Erica Pike, Brian Rivera and Sean Orlowicz  
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

### Introduction

Immunoassay, nano-LC systems, and 2D-LC-MS/MS methods are commonly used to reach such low detection levels for Oxytocin (OT) and Arginine-vasopressin (AVP); however, these methodologies also have limitations such as assay reproducibility issues, facility instrument limitations, and high method development and validation costs.

In this study, we provide an accurate and reproducible method to analyze both OT and AVP in one injection.



### Materials and Methods

#### Reagents and Chemicals

Oxytocin, vasopressin, and octreotide standards were purchased from Sigma-Aldrich.

#### Experimental Conditions


##### Solid Phase Extraction Method Development

300  $\mu$ L of plasma/serum was treated with 300  $\mu$ L 4 % phosphoric acid and 50  $\mu$ L of internal standard (500 ng/mL of Octreotide) in water and mixed. Strata-X, Strata-X-C, and Strata-X-CW were evaluated to determine the optimal solid phase extraction sorbent (**Figure 1**). For the final selected sorbent, Strata-X-CW, wash and elution solvents were optimized (**Figures 2** and **3**). Although Strata-X performed well for AVP, only Strata-X-CW was able to provide acceptable recoveries for both OT and AVP.


#### LC-MS/MS Conditions

LC-MS/MS was performed using a Luna 3  $\mu$ m PFP(2) 50 x 2.0 mm HPLC column ([00B-4447-B0](#)) on an Agilent® 1200 LC system (Agilent Technologies, Palo Alto, CA, USA) with an upper pressure limit of 400 bar, equipped with a binary pump, autosampler and interfaced with an API 5000™ triple quadrupole mass spectrometer (AB SCIEX, Framingham, MA, USA). The ionization source was electrospray ionization (ESI) analyzed in positive ion mode. Ionization source parameters and LC running conditions are indicated.


**Figure 1. Response of OT and AVP using Various SPE Sorbents**  
**SPE Sorbent Selection**



**Figure 2. Response of OT and AVP of 2<sup>nd</sup> Wash Optimization using Strata-X-CW**  
**2<sup>nd</sup> Wash Optimization**



**Figure 3. Response of OT and AVP Under Various Elution Strengths using Strata-X-CW**  
**Elution Solvent Optimization**



#### Optimized SPE Method

96-Well Plate: Strata-X-CW, 30 mg/well  
 Part No.: [BE-S035-TGB](#)  
 Condition: 1 mL Methanol  
 Equilibrate: 1 mL Water  
 Load: Pretreated plasma/serum  
 Wash 1: 1 mL 4 %  $H_3PO_4$   
 Wash 2: 1 mL Methanol/Water (30:70)  
 Dry: 3 to 4 minutes under 10<sup>-1</sup> Hg vacuum  
 Elute: 2x 0.75 mL 1 % TFA in Acetonitrile/Methanol (50:50)  
 Dry down: Dry down completely under a stream of nitrogen @ 50 °C  
 Reconstitute: 100  $\mu$ L of 1 % TFA in Mobile Phase A/Mobile Phase B (80:20)  
 Mobile Phase A: 0.1 % Formic acid; B: Methanol/Acetonitrile (50:50) with 0.1 % Formic acid



# APPLICATIONS

## Results and Discussion

**Figure 4** and **Figure 5** show extracted ion chromatograms at QCL levels of 0.500 ng/mL. **Figure 6** shows a representative chromatogram at analyte levels of 500 ng/mL, showing that the Luna PFP(2) HPLC column provided good selectivity and sensitivity for both Oxytocin and ARG-Vasopressin in a single injection.

**Table 2** shows the accuracy and precision of three QC levels. The results showed that the assay was accurate, precise, and reproducible. Linearity was determined to be acceptable from 0.2 - 500 ng/mL (**Figures 7** and **8**).

### Ionization Source Parameters:

Gas 1 & Gas 2: 25  
CAD: 8  
Cur: 25  
IS: 5500  
Temp: 450  
ihe: ON  
DP: 120  
EP: 10

Column: Luna<sup>®</sup> 3 μm PFP(2)

Dimensions: 50 x 2.0 mm

Part No.: [00B-4447-B0](#)

Mobile Phase: A: 0.1% Formic acid  
B: Methanol/Acetonitrile (50:50) with 0.1% Formic acid

Gradient: Time (min)    B (%)  
0              10  
0.2            10  
0.5            30  
3.5            30  
3.51          70  
4              70  
4.01          10  
5              10

Flow Rate: 0.45 mL/min

Injection: 10 μL

Temperature: 40 °C

Detection: SCIEX<sup>®</sup> API 5000™

**Table 1.** MRM Transitions for OT and AVP

Analyte Peak Name	Q1 (Da)	Q3 (Da)	Dwell (msec)	CE	CXP
Oxytocin 1	1007.9	723.4	75	39	15
Oxytocin 2	504.8	86.2	75	35	15
Vasopressin 1	542.5	328.6	75	28	15
Vasopressin 2	542.5	120.1	75	28	15
Octreotide (IS)	510.5	120.1	75	30	13


Q1. Quantitation mass transitions

Q2. Confirmation mass transitions


## Conclusion

In this study, we combined OT and AVP and analyzed them within a single method. To maximize assay recoveries, the 2nd strong wash and elution solvents have been optimized. We also provided stable MRM transitions for both OT and AVP, the assay dynamic range is 0.2 - 500 ng/mL for both compounds with precision less than 13.9 % and accuracy less than 7.4 %. This method would provide a good starting point for reference labs as an alternative approach to immunoassay. Although our resulting method was accurate at concentration ranges of 0.2 - 500 ng/mL, the LLOQ level could be decreased significantly if coupled with a nano-LC system or HRMS.


**Figure 4.** Oxytocin Extracted Ion Chromatograms, QCL (0.500 ng/mL)



**Figure 5.** ARG-Vasopressin Extracted Ion Chromatograms, QCL (0.500 ng/mL)




**Figure 6.** Representative Chromatogram of ARG-Vasopressin and Oxytocin




# APPLICATIONS

**Figure 7.** Representative Curve of Oxytocin



**Figure 8.** Representative Curve of ARG-Vasopressin



**Table 2.** Accuracy and Precision

Nominal Conc. (ng/mL)	QCL	QCM	QCH
	0.5	10	400
<b>Oxytocin (OT)</b>			
Mean Conc. Fund (ng/mL)	0.521	10.1	382
STDV	0.025	0.597	25.8
CV %	4.72	5.94	6.76
Accuracy (%)	104	101	95.5
<b>ARG-Vasopressin (AVP)</b>			
Mean Conc. Fund (ng/mL)	0.473	10.2	370
STDV	0.666	0.367	23.3
CV %	13.9	3.59	6.29
Accuracy (%)	94.5	102	92.6



Have questions or want more details on implementing this method? We would love to help!  
 Visit [www.phenomenex.com/LiveChat](http://www.phenomenex.com/LiveChat) to get in touch with one of our Technical Specialists

# APPLICATIONS

## Strata®-X-CW SPE Ordering Information

Format	Sorbent Mass	Part Number	Unit
<b>Tube</b>			
	30 mg	8B-S035-TAK**	1 mL (100/box)
	30 mg	8B-S035-TBJ	3 mL (50/box)
	60 mg	8B-S035-UBJ**	3 mL (50/box)
	100 mg	8B-S035-ECH	6 mL (30/box)
	200 mg	8B-S035-FBJ	3 mL (50/box)
	200 mg	8B-S035-FCH	6 mL (30/box)
	500 mg	8B-S035-HBJ	3 mL (50/box)
	500 mg	8B-S035-HCH	6 mL (30/box)
<b>Giga™ Tube</b>			
	1 g	8B-S035-JDG	12 mL (20/box)
	1 g	8B-S035-JEG	20 mL (20/box)
	2 g	8B-S035-KEG	20 mL (20/box)
	5 g	8B-S035-LFF	60 mL (16/box)
<b>96-Well Plate</b>			
	10 mg	8E-S035-AGB	2 Plates/Box
	30 mg	8E-S035-TGB	2 Plates/Box
	60 mg	8E-S035-UGB	2 Plates/Box
<b>96-Well Microelution Plate</b>			
	2 mg	8M-S035-4GA	ea

\*\*Tab-less tubes available. Contact Phenomenex for details.



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.  
[www.phenomenex.com/behappy](http://www.phenomenex.com/behappy)

## Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions which may be viewed at [www.phenomenex.com/TermsAndConditions](http://www.phenomenex.com/TermsAndConditions).

## Trademarks

Luna and Strata are registered trademarks and SecurityGuard, Giga, MidBore, and BE-HAPPY are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc. API 5000 is a trademark of AB SCIEX™ Pte. Ltd. SCIEX is a registered trademark and AB SCIEX is being used under license.

Strata-X is patented by Phenomenex. U.S. Patent No. 7,119,145

SecurityGuard is patented by Phenomenex. U.S. Patent No. 6,162,362.

*Caution: this patent only applies to the analytical-sized guard cartridge holder, and does not apply to SemiPrep, PREP, or ULTRA holders, or to any cartridges.*

**FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.**

© 2020 Phenomenex, Inc. All rights reserved.

**Australia**  
t: +61 (0)2-9428-6444  
auinfo@phenomenex.com

**Austria**  
t: +43 (0)1-319-1301  
anfrage@phenomenex.com

**Belgium**  
t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
beinfo@phenomenex.com

**Canada**  
t: +1 (800) 543-3681  
info@phenomenex.com

**China**  
t: +86 400-606-8099  
cninfo@phenomenex.com

**Denmark**  
t: +45 4824 8048  
nordicinfo@phenomenex.com

**www.phenomenex.com**

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at [international@phenomenex.com](mailto:international@phenomenex.com)

**Finland**  
t: +358 (0)9 4789 0063  
nordicinfo@phenomenex.com

**France**  
t: +33 (0)1 30 09 21 10  
franceinfo@phenomenex.com

**Germany**  
t: +49 (0)6021-58830-0  
anfrage@phenomenex.com

**India**  
t: +91 (0)40-3012 2400  
indiainfo@phenomenex.com

**Ireland**  
t: +353 (0)1 247 5405  
eireinfo@phenomenex.com

**Italy**  
t: +39 051 6327511  
italiainfo@phenomenex.com

**Luxembourg**  
t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**Mexico**  
t: 01-800-844-5226  
technicomx@phenomenex.com

**The Netherlands**  
t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**New Zealand**  
t: +64 (0)9-4780951  
nzinfo@phenomenex.com

**Norway**  
t: +47 810 02 005  
nordicinfo@phenomenex.com

**Poland**  
t: +48 22 104 21 72  
pl-info@phenomenex.com

**Portugal**  
t: +351 221 450 488  
ptinfo@phenomenex.com

**Singapore**  
t: +65 800-852-3944  
sginfo@phenomenex.com

**Spain**  
t: +34 91-413-8613  
espinfo@phenomenex.com

**Sweden**  
t: +46 (0)8 611 6950  
nordicinfo@phenomenex.com

**Switzerland**  
t: +41 (0)61 692 20 20  
swissinfo@phenomenex.com

**Taiwan**  
t: +886 (0) 0801-49-1246  
twinfo@phenomenex.com

**United Kingdom**  
t: +44 (0)1625-501367  
ukinfo@phenomenex.com

**USA**  
t: +1 (310) 212-0555  
info@phenomenex.com

**All other countries/regions**  
**Corporate Office USA**  
t: +1 (310) 212-0555  
info@phenomenex.com